Neonatal Opioid Withdrawal Syndrome
Full update March 2021
Neonatal
opioid withdrawal syndrome (NOWS), a specific type of neonatal abstinence
syndrome (NAS), occurs when a baby withdraws from opiates the mother took or
used chronically during pregnancy.2,13 The chart below answers common questions about NOWS.
Question |
Answer/Pertinent Information |
What are the signs
and symptoms of neonatal opioid withdrawal syndrome? |
Symptoms typically occur within 24 to 72
hours of delivery.1
|
How should newborns be screened
for neonatal opioid withdrawal syndrome? |
Take a thorough history about maternal
drug use, including prescription and non-prescription products.1
Urine and/or meconium (newborn’s first
stool) can be tested for opiates.2,12,13
Several
screening tools are available to assess the baby’s symptoms. Use a screening tool to assist with
facility NOWS treatment, titration, and weaning protocol parameters. Examples include:2
|
How is the Modified
Finnegan Scoring System used? |
Scoring typically begins within two
hours of birth, and is re-evaluated every few hours (e.g., every two to four
hours).12
Most institutions and studies define
neonatal withdrawal as a score of ≥8.1,2 The Modified
Finnegan Scoring System evaluates signs and symptoms in the following areas:
Facility
protocols then determine interventions based on individual, average, or
consecutive scores.1,2 Examples of
existing protocols can be found at:
|
What supportive
measures are recommended? |
The “eat, sleep, console” or ESC method
is a strategy used in the management of NOWS.
The ESC method involves assessing if babies can eat well, sleep undisturbed,
or be consoled within ten minutes before using medications.24 In addition, facilities may encourage
the use of prn medications instead of using scheduled doses.25 Some data suggest that using ESC, instead
of traditional scoring methods, may reduce length of stay [Evidence Level
B-3].24,27 The nonpharmacologic suggestions below are
included as part of ESC, but also encouraged even if other scoring methods
are used instead of the ESC method at your facility.
|
When are medications
appropriate? |
Follow facility protocols for
pharmacologic interventions. Using a
protocol may be more impactful than the choice of medication used for
weaning.7
Many protocols initiate medications
using the following or similar cutoffs:4,5
|
Which
medications should be used to treat neonatal opioid
withdrawal syndrome? |
Start with opioid
replacement.7
Adjunctive medications most often
include clonidine or phenobarbital.7,13
|
How should morphinea be dosed for
neonatal opioid withdrawal syndrome? |
Initial oral dose: 0.05 to 0.1 mg/kg every three to four hours.5,17
Max dose: 2.3 mg/kg in 24 hours.17 Add additional therapy (e.g., clonidine)
when total daily morphine doses are >1 to 1.6 mg/kg or in patients with
significant diarrhea or insomnia.5,17 Consider weaning morphine once symptoms
are stable and controlled (e.g., Modified Finnegan scores consistently <8)
for about 24 to 48 hours. Reduce doses
by about 10% to 20% every 24 to 48 hours.5,17
May discharge home 48 hours after discontinuation, as long as all Modified Finnegan scores remain <8 off therapy.7 |
How should methadonea be dosed for neonatal opioid withdrawal syndrome? |
Initial oral dose: 0.05 mg/kg every 12 hours.18
Max dose: 0.2 mg/kg/dose every six hours.17 Consider weaning methadone once symptoms
are stable and controlled (e.g., Modified Finnegan scores consistently <8)
for about 24 to 48 hours.17 Tapering schedules vary and may be slower
(e.g., lower methadone by 0.02 to 0.05 mg per dose, either once or twice
weekly) compared to tapering off morphine.9 May discharge home 72 hours after discontinuation7 or some protocols may allow for tapers to be completed at home due to the slow nature of the taper in situations where caregivers can demonstrate the ability to measure appropriate doses.9 |
How should buprenorphinea be dosed for neonatal opioid withdrawal syndrome? |
Initial sublingual dose: 4 to 6 mcg/kg/dose given every eight hours.11,15
Max dose: 60 mcg/kg/day.11 Consider weaning newborns off of buprenorphine by reducing the dose by about 10% per
day if the total of the previous three Modified Finnegan scores is less than
18. Buprenorphine can be discontinued
once the dose has been reduced to 10% of the initial dose.11,22 Monitor newborns for at least 48 hours
after discontinuation prior to discharge.11 |
How should clonidinea be dosed for neonatal opioid withdrawal syndrome? |
Initial
oral dose: 0.5 to 1 mcg/kg every three to six hours1,17 Higher doses (e.g., 1.5
mcg/kg/dose every four to six hours) can be used after the second week of
life in newborns with severe NOWS.17
Max dose: 24 mcg/kg/day.20 May be added to morphine when total
daily morphine doses are >1 to 1.6 mg/kg or in patients with significant
diarrhea or insomnia.5,17 Wean clonidine slowly (e.g., reduce
doses by 0.25 mcg/kg every six hours, reduce dose by 25% per day by
increasing dosing interval [for example, change every six-hour dosing to
every eight-hour dosing]) over about three days starting the taper AFTER
morphine is discontinued.17
Monitor blood pressure for at least 48 hours after discontinuation of clonidine before discharging home.21 |
How should phenobarbitala be dosed for
neonatal opioid withdrawal syndrome? |
Initial oral dose: 10 to 20 mg/kg loading dose. Then starting 12 hours later, give 1.5 to 2.5
mg/kg every 12 hours or 3 to 5 mg/kg every 24 hours.5,17 Note: loading dose is NOT necessary in the
absence of seizures.17
Max dose: Specific maximum dosage not available.8 May discontinue (not necessary to taper phenobarbital, though some protocols may reduce dose by 20% each day5,13) after weaning has been completed for other medications (e.g., morphine).17 May discharge after discontinuation or some protocols may allow newborns to go home during phenobarbital taper.13 |
- Facility protocol may vary from these doses. These are example doses summarized from available
NOWS protocols and clinical trial data.
Levels of Evidence
In accordance with our goal of providing Evidence-Based information, we are citing the LEVEL OF EVIDENCE for the clinical recommendations we publish.
Level |
Definition |
Study Quality |
A |
Good-quality patient-oriented evidence.* |
|
B |
Inconsistent or limited-quality patient-oriented evidence.* |
|
C |
Consensus; usual practice; expert opinion; disease-oriented evidence (e.g., physiologic or surrogate endpoints); case series for studies of diagnosis, treatment, prevention, or screening. |
*Outcomes that matter to patients (e.g., morbidity, mortality, symptom improvement, quality of life).
RCT = randomized controlled trial; SR = systematic review [Adapted from Ebell MH, Siwek J, Weiss BD, et al. Strength of Recommendation Taxonomy (SORT): a patient-centered approach to grading evidence in the medical literature. Am Fam Physician 2004;69:548-56. http://www.aafp.org/afp/2004/0201/p548.pdf.]
References
- Hudak ML, Tan RC, Committee on Drugs, Committee on Fetus and Newborn. Neonatal drug withdrawal. Pediatrics 2012;129:e540-60.
- Holmes AP. NICU primer for pharmacists. Chapter 5: neonatal abstinence syndrome. 2016. https://www.ashp.org/-/media/store-files/p4757-sample-chapter-5.ashx. (Accessed February 18, 2021).
- MacMullen NJ, Dulski LA, Blobaum P. Evidence-based interventions for neonatal abstinence syndrome. Pediatr Nurs 2014;40:165-72, 203.
- University of Texas kids. University Health System: modified Finnegan’s neonatal abstinence scoring tool. June 2015. https://www.universityhealthsystem.com/~/media/files/clinical-pathways/modified-finnegans-nas-scoring-tool-pt-approved-0615.pdf?la=en. (Accessed February 18, 2021).
- Children’s Hospital of Philadelphia. Inpatient pathway for the evaluation/treatment of infants with neonatal abstinence syndrome. Revised January 2019. http://www.chop.edu/clinical-pathway/neonatal-abstinence-syndrome-clinical-pathway. (Accessed February 18, 2021).
- Joint Commission. Quick safety. Managing neonatal abstinence syndrome. September 2016. https://www.jointcommission.org/assets/1/23/Quick_Safety_Issue_27_Sep_2016.pdf. (Accessed February 18, 2021).
- McQueen K, Murphy-Oikonen
J. Neonatal abstinence syndrome. N Engl J Med 2016;375:2468-79.
- Clinical Pharmacology powered by ClinicalKey. Tampa (FL): Elsevier. 2021. http://www.clinicalkey.com. (Accessed February 22, 2021).
- Johnston A, Metayer J, Robinson E. Management of neonatal opioid withdrawal. https://pqcnc-documents.s3.amazonaws.com/nas/nasresources/VCHIP_5NEONATAL_GUIDELINES.pdf. (Accessed February 18, 2021).
- Dow K, Ordean A, Murphy-Oikonen J, et al. Neonatal abstinence syndrome clinical practice guidelines for Ontario. J Popul Ther Clin Pharmacol 2012;19:e488-506.
- Kraft WK, Adeniyi-Jones SC, Chervoneva I, et al. Buprenorphine for the treatment of neonatal abstinence syndrome. N Engl J Med 2017;376:2341-8.
- HSHS St. Vincent, St. Mary’s, St. Nicholas. Neonatal abstinence syndrome. https://wispqc.org/wp-content/uploads/HSHSSt.Vincent.pdf. (Accessed February 18, 2021).
- Patrick SW, Barfield WD, Poindexter BB, et al. Neonatal opioid withdrawal syndrome. Pediatrics 2020;146:e2020029074.
- Davis JM, Shenberger J, Terrin N, et al. Comparison of safety and efficacy of methadone vs morphine for treatment of neonatal abstinence syndrome: a randomized clinical trial. JAMA Pediatr 2018;172:741-8.
- Lee JJ, Chen J, Eisler L, et al. Comparative effectiveness of opioid replacement agents for neonatal opioid withdrawal syndrome: a systematic review and meta-analysis. J Perinatol 2019;39:1535-45.
- Alabama Perinatal Quality Collaborative. Neonatal opioid withdrawal syndrome initiative: hospital team toolkit. https://cpb-us-w2.wpmucdn.com/sites.uab.edu/dist/1/156/files/2020/11/NOWS-Toolkit-Checklist.pdf. (Accessed February 22, 2021).
- Government of Indiana. Perinatal substance use taskforce. NAS pharmacologic therapy protocol. https://www.in.gov/laboroflove/files/NAS%20Pharmacologic%20Therapy%20Protocol.pdf. (Accessed February 22, 2021).
- University of Iowa Children’s Hospital. Identifying neonatal abstinence syndrome (NAS) and treatment guidelines. November 2014. https://uichildrens.org/sites/default/files/neonatal_abstinence_syndrome_treatment_guidelines_feb2013_revision-1.pdf. (Accessed February 22, 2021).
- D’Abaco E. Does the addition of clonidine to opioid therapy improve outcomes in infants with neonatal abstinence syndrome? J Paediatr Child Health 2021;57:155-9.
- NationwideChildrens.org. Neonatal abstinence syndrome management: initiation, escalation and stabilization. https://www.nationwidechildrens.org/Document/Get/168003. (Accessed February 22, 2021).
- Golisano Children’s Hospital of Southwest Florida- NICU. Management of the infant with neonatal abstinence syndrome. https://health.usf.edu/-/media/Files/Public-Health/Chiles-Center/FPQC/Golisano-NAS-guideline.ashx?la=en&hash=731C989F9BFDBFFE3C9D78F0C292D18055DB3221. (Accessed February 22, 2021).
- Kraft WK, van den Anker JN. Pharmacologic management of the opioid neonatal abstinence syndrome. Pediatr Clin North Am 2012;59:1147-65.
- Siu A, Robinson CA. Neonatal abstinence syndrome: essentials for the practitioner. J Pediatr Pharmacol Ther 2014;19:147–55.
- American Academy of Pediatrics News. Alternative treatment approach for neonatal abstinence syndrome may shorten hospital stay. May 4, 2017. https://www.aappublications.org/news/2017/05/04/PASNAS050417. (Accessed February 23, 2021).
- Allen A. Multi-site statewide collaboration for standardization of care for opioid exposed newborns. August 11, 2020. https://www.aappublications.org/news/2020/08/11/standardization-care-opioid-exposed-newborns-hospitalpediatrics. (Accessed February 23, 2021).
- Illinois prenatal quality collaborative. Sample decision tree flowchart eat, sleep, console method. https://ilpqc.org/wp-content/docs/toolkits/MNO-Neo/Sample-Decision-Tree-Flowchart-ESC.pdf. (Accessed February 26, 2021).
- Grossman MR, Lipshaw M, Osborn RR, Berkwitt AK. A novel approach to assessing infants with neonatal abstinence syndrome. Hosp Pediatr 2018;8:1-6. [abstract].
Cite this document as follows: Clinical Resource, Neonatal Opioid Withdrawal Syndrome. Hospital Pharmacist’s Letter/Pharmacy Technician’s Letter. March 2021. [370322]